Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Galapagos Surges On New CEO and Upgrade News

Published 27/01/2022, 18:00
Updated 27/01/2022, 18:00
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Shares of Belgian pharmaceutical research company Galapagos NV ADR (NASDAQ:GLPG) are up more than 21% a day after the company appointed its new CEO.

Citi analysts upgraded the stock on Thursday morning.

The drug maker announced the appointment of Paul Stoffels as CEO, effective April 1. Stoffel was previously the chief scientific officer of Johnson & Johnson (NYSE:JNJ). Last year, he retired but will take over at the troubled Belgian firm when Galapagos' CEO and co-founder Onno van de Stolpe steps into retirement.

Galapagos has faced several difficulties recently, one of which is a $5 billion alliance with Gilead Sciences (NASDAQ:GILD) not working out. 

Citi analyst Peter Verdult upgraded the stock to buy from neutral. Verdult said the company's shares offer a more attractive risk/reward.

The analyst also pointed to the appointment of Stoffel and deployment opportunities for the company's 5 billion euros cash pile. As a result, the analyst also put a "positive catalyst watch" on the shares.

On Wednesday, Greenlight Capital revealed new long positions in Galapagos in its quarterly letter.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.